Omthera Pharmaceuticals (OMTH) - NASDAQ
OMTH is defunct.
  • May 7, 2013, 11:29 AM

    BofA initiates recently public Omthera Pharmaceuticals (OMTH +7.5%) at Buy with a $10 price target, saying the company "has a compelling valuation compared to the only other omega-3 pure play [and] Epanova has significant growth potential [but] does not have to become a blockbuster" for the stock to rise. Similarly, Leerink Swann starts the stock at Outperform ($12 price target) citing a positive outlook for Epanova, and Piper Jaffray assumes coverage at Overweight with a target of $15.

    | May 7, 2013, 11:29 AM
Company Description
We are an emerging specialty pharmaceutical company focused on the development and commercialization of new therapies for abnormalities in blood lipids, referred to as dyslipidemia, and the treatment of cardiovascular disease. Epanova, currently our sole product candidate, is a late-stage,... More
Sector: Healthcare
Industry: Drugs - Generic
Country: United States